《大行報告》花旗料東亞(00023.HK)出售壽險業務作價或高預期 派特別息機會增
花旗發表報告表示,據報友邦保險(01299.HK)及鄭家純投資的中策集團(00235.HK)入圍競投東亞銀行(00023.HK)壽險資產的最後一輪,中策今日公布已就東亞人壽投標程序第二階段提交要約。該行料上述交易最快於今個月內公布。
報告又指,東亞人壽於截至去年上半年整體資產為22.84億元,佔東亞集團2.5%,而據報道作價介乎5至6億美元(約39至47億港元),相當於市帳率1.7至2倍,遠高於該行預期,更料派特別息機會上升。該行認為,東亞需要進行更多業務重組,維持其「沽售」評級,目標價為14.6元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.